{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T06:04:12Z","timestamp":1794895452745,"version":"4.9.1"},"reference-count":22,"publisher":"American Society for Microbiology","issue":"11","license":[{"start":{"date-parts":[[2004,11,1]],"date-time":"2004-11-01T00:00:00Z","timestamp":1099267200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["J Clin Microbiol"],"published-print":{"date-parts":[[2004,11]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Although both broth microdilution (BMD) and disk diffusion (DD) are listed by NCCLS as acceptable methods for testing\n            <jats:italic>Acinetobacter<\/jats:italic>\n            spp. for antimicrobial susceptibility, few studies have compared the results generated by the two methods. We tested 196 isolates of\n            <jats:italic>Acinetobacter<\/jats:italic>\n            spp. from nine U.S. hospitals and from the Centers for Disease Control culture collection by using BMD and DD and clinically appropriate antimicrobial agents. Categorical results for amikacin, ciprofloxacin, gatifloxacin, gentamicin, imipenem, levofloxacin, meropenem, tobramycin, and trimethoprim-sulfamethoxazole were comparable for the two methods: there was only one very major (VM) error, with tobramycin, and only one major (M) error, with meropenem, when DD results were compared with BMD results. However, VM errors were frequent with the \u03b2-lactams and \u03b2-lactam-\u03b2-lactam inhibitor combinations, while M errors were often observed with tetracyclines. For BMD, tests frequently exhibited subtle growth patterns that were difficult to interpret, especially for \u03b2-lactams. If subtle growth (i.e., granular, small button, or \u201cstarry\u201d growth) was considered positive, error rates between BMD and DD were unacceptably high for ampicillin-sulbactam (VM error, 9.8%; minor [m] error, 16.1%), piperacillin (VM error, 5.7%; m error, 13.5%), piperacillin-tazobactam (VM error, 9.3%; m error, 12.9%), ceftazidime (VM error, 6.2%; m error, 11.4%), cefepime (VM error, 6.2%; m error, 13.0%), cefotaxime (m error, 21.2%), ceftriaxone (m error, 23.3%), tetracycline (M error, 11.4%; m error, 32.1%), and doxycycline (M error, 2.6%). When subtle growth patterns were ignored, the agreement still did not achieve acceptable levels. To determine if the problems with BMD testing occurred in other laboratories, we sent frozen BMD panels containing \u03b2-lactam drugs and nine isolates to six labs with experience in performing BMD and DD. Among these laboratories, cefepime MICs ranged from \u22648 to \u226532 \u03bcg\/ml for four of the nine strains, confirming the problem in interpreting BMD results. Discrepancies between the categorical interpretations of BMD and DD tests were noted primarily with cefepime and piperacillin, for which the BMD results were typically more resistant. Clinical laboratories should be aware of these discrepancies. At present, there are no data to indicate which method provides more clinically relevant information.\n          <\/jats:p>","DOI":"10.1128\/jcm.42.11.5102-5108.2004","type":"journal-article","created":{"date-parts":[[2004,11,5]],"date-time":"2004-11-05T01:09:22Z","timestamp":1099616962000},"page":"5102-5108","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":69,"title":["Antimicrobial Susceptibility Testing of\n            <i>Acinetobacter<\/i>\n            spp. by NCCLS Broth Microdilution and Disk Diffusion Methods"],"prefix":"10.1128","volume":"42","author":[{"given":"Jana M.","family":"Swenson","sequence":"first","affiliation":[{"name":"Division of Healthcare Quality Promotion, Epidemiology and Laboratory Branch, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George E.","family":"Killgore","sequence":"additional","affiliation":[{"name":"Division of Healthcare Quality Promotion, Epidemiology and Laboratory Branch, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred C.","family":"Tenover","sequence":"additional","affiliation":[{"name":"Division of Healthcare Quality Promotion, Epidemiology and Laboratory Branch, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","first-page":"2339","year":"2000","unstructured":"Allen, D. M., and B. J. Hartman. 2000. Acinetobacter species, p. 2339-2344. In G. L. Mandell, J. E. Bennett, and R. Dolin (ed.), Principles and practices of infectious diseases. Churchill Livingstone, Inc., Philadelphia, Pa.","journal-title":"Principles and practices of infectious diseases"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/42.6.793"},{"key":"e_1_3_2_4_2","first-page":"252","volume":"29","year":"1999","unstructured":"Fridkin, S. K., C. D. Steward, J. R. Edwards, E. R. Pryor, J. E. McGowan, Jr., L. Archibald, R. P. Gaynes, F. C. Tenover, and Project Intensive Care Antimicrobial Resistance Epidemiology Hospitals. 1999. Surveillance of antimicrobial use and antimicrobial resistance in U.S. hospitals: project ICARE phase 2. Clin. Infect. Dis.29:252.","journal-title":"Clin. Infect. Dis."},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(02)00503-5"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1086\/320183"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.39.1.183-190.2001"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.1.268-273.2003"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.5.1586-1592.2004"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1469-0691.2002.00415.x"},{"key":"e_1_3_2_11_2","unstructured":"NCCLS. 2000. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard 5th ed. NCCLS document M7-A5. NCCLS Wayne Pa."},{"key":"e_1_3_2_12_2","unstructured":"NCCLS. 2000. Performance standards for antimicrobial disk susceptibility tests. Approved standard 7th ed. NCCLS document M2-A7. NCCLS Wayne Pa."},{"key":"e_1_3_2_13_2","unstructured":"NCCLS. 2001. Development of in vitro susceptibility testing and quality control parameters. Approved guideline 2nd ed. NCCLS document M23-A2. NCCLS Wayne Pa."},{"key":"e_1_3_2_14_2","unstructured":"NCCLS. 2002. Performance standards for antimicrobial susceptibility testing. Twelfth informational supplement. NCCLS document M100-S12. NCCLS Wayne Pa."},{"key":"e_1_3_2_15_2","unstructured":"NCCLS. 2003. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard 6th ed. NCCLS document M7-A6. NCCLS Wayne Pa."},{"key":"e_1_3_2_16_2","unstructured":"NCCLS. 2003. Performance standards for antimicrobial disk susceptibility tests. Approved standard 8th ed. NCCLS document M2-A8. NCCLS Wayne Pa."},{"key":"e_1_3_2_17_2","unstructured":"NCCLS. 2004. Performance standards for antimicrobial disk susceptibility testing. Fourteenth informational supplement. NCCLS document M100-514. NCCLS Wayne Pa."},{"key":"e_1_3_2_18_2","first-page":"749","year":"2003","unstructured":"Schreckenberger, P. C., M. I. Daneshvar, R. S. Weyant, and D. G. Hollis. 2003. Acinetobacter, Achromobacter, Chryseobacterium, Moraxella, and other nonfermentative gram-negative rods, p. 749-779. In P. R. Murray, E. J. Baron, J. H. Jorgensen, M. A. Pfaller, and R. H. Yolken (ed.), Manual of clinical microbiology. ASM Press, Washington, D.C.","journal-title":"Manual of clinical microbiology"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.35.11.2819-2825.1997"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1086\/374847"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.33.1.11-15.1995"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.37.3.758-761.1999"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkf043"}],"container-title":["Journal of Clinical Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/JCM.42.11.5102-5108.2004","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/JCM.42.11.5102-5108.2004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,5]],"date-time":"2022-03-05T02:43:30Z","timestamp":1646448210000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/JCM.42.11.5102-5108.2004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,11]]},"references-count":22,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2004,11]]}},"alternative-id":["10.1128\/JCM.42.11.5102-5108.2004"],"URL":"https:\/\/doi.org\/10.1128\/jcm.42.11.5102-5108.2004","relation":{},"ISSN":["0095-1137","1098-660X"],"issn-type":[{"value":"0095-1137","type":"print"},{"value":"1098-660X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,11]]},"assertion":[{"value":"2004-04-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2004-07-19","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2004-11-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}